A Compendium of DIS3 Mutations and Associated Transcriptional Signatures in Plasma Cell Dyscrasias

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Aug 26

PMID 26305418

Citations 27

Authors

Marta Lionetti

Marzia Barbieri

Katia Todoerti

Luca Agnelli

Sonia Fabris

Giovanni Tonon

Simona Segalla

Ingrid Cifola

Eva Pinatel

Pierfrancesco Tassone

Pellegrino Musto

Luca Baldini

Antonino Neri

Affiliations

Soon will be listed here.

Abstract

DIS3 is a catalytic subunit of the human exosome complex, containing exonucleolytic (RNB) and endonucleolytic (PIN) domains, recently found mutated in multiple myeloma (MM), a clinically and genetically heterogeneous form of plasma cell (PC) dyscrasia. We analyzed by next-generation sequencing (NGS) the DIS3 PIN and RNB domains in purified bone marrow PCs from 164 representative patients, including 130 cases with MM, 24 with primary PC leukemia and 10 with secondary PC leukemia. DIS3 mutations were found respectively in 18.5%, 25% and 30% of cases. Identified variants were predominantly missense mutations localized in the RNB domain, and were often detected at low allele frequency. DIS3 mutations were preferentially carried by IGH-translocated/nonhyperdiploid patients. Sequential analysis at diagnosis and relapse in a subset of cases highlighted some instances of increasing DIS3 mutation burden during disease progression. NGS also revealed that the majority of DIS3 variants in mutated cases were comparably detectable at transcriptional level. Furthermore, gene expression profiling analysis in DIS3-mutated patients identified a transcriptional signature suggestive for impaired RNA exosome function. In conclusion, these data further support the pathological relevance of DIS3 mutations in plasma cell dyscrasias and suggest that DIS3 may represent a potential tumor suppressor gene in such disorders.

Citing Articles

Selection on synonymous sites: the unwanted transcript hypothesis.

Radrizzani S, Kudla G, Izsvak Z, Hurst L Nat Rev Genet. 2024; 25(6):431-448.

PMID: 38297070 DOI: 10.1038/s41576-023-00686-7.

RNA processing mechanisms contribute to genome organization and stability in B cells.

Miglierina E, Ordanoska D, Le Noir S, Laffleur B Oncogene. 2024; 43(9):615-623.

PMID: 38287115 PMC: 10890934. DOI: 10.1038/s41388-024-02952-2.

pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods.

Behdenna A, Colange M, Haziza J, Gema A, Appe G, Azencott C BMC Bioinformatics. 2023; 24(1):459.

PMID: 38057718 PMC: 10701943. DOI: 10.1186/s12859-023-05578-5.

depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification.

Favasuli V, Ronchetti D, Silvestris I, Puccio N, Fabbiano G, Traini V Haematologica. 2023; 109(1):231-244.

PMID: 37439377 PMC: 10772536. DOI: 10.3324/haematol.2023.283274.

: The Enigmatic Gene in Multiple Myeloma.

Ohguchi Y, Ohguchi H Int J Mol Sci. 2023; 24(4).

PMID: 36835493 PMC: 9958658. DOI: 10.3390/ijms24044079.

References

. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-57. View

Lionetti M, Fabris S, Cutrona G, Agnelli L, Ciardullo C, Matis S . High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol. 2014; 165(5):629-39. DOI: 10.1111/bjh.12800. View

Keats J, Chesi M, Egan J, Garbitt V, Palmer S, Braggio E . Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5):1067-76. PMC: 3412330. DOI: 10.1182/blood-2012-01-405985. View

Segalla S, Pivetti S, Todoerti K, Chudzik M, Giuliani E, Lazzaro F . The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. Nucleic Acids Res. 2015; 43(10):5182-93. PMC: 4446438. DOI: 10.1093/nar/gkv387. View

Lorentzen E, Basquin J, Tomecki R, Dziembowski A, Conti E . Structure of the active subunit of the yeast exosome core, Rrp44: diverse modes of substrate recruitment in the RNase II nuclease family. Mol Cell. 2008; 29(6):717-28. DOI: 10.1016/j.molcel.2008.02.018. View

Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A . Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015; 6(19):17543-58. PMC: 4627327. DOI: 10.18632/oncotarget.4028. View

Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S . Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015; 6(27):24205-17. PMC: 4695180. DOI: 10.18632/oncotarget.4434. View

Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L . Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013; 19(12):3247-58. DOI: 10.1158/1078-0432.CCR-12-3461. View

Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, DAnca M . Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. Genes Chromosomes Cancer. 2013; 53(2):154-67. DOI: 10.1002/gcc.22127. View

10.

Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S . Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol. 2012; 88(1):16-23. DOI: 10.1002/ajh.23339. View

11.

Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

12.

Bolli N, Avet-Loiseau H, Wedge D, Van Loo P, Alexandrov L, Martincorena I . Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997. PMC: 3905727. DOI: 10.1038/ncomms3997. View

13.

Weissbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M . The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2014; 169(1):57-70. DOI: 10.1111/bjh.13256. View

14.

Lohr J, Stojanov P, Carter S, Cruz-Gordillo P, Lawrence M, Auclair D . Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1):91-101. PMC: 4241387. DOI: 10.1016/j.ccr.2013.12.015. View

15.

Eckard S, Rice G, Fabre A, Badens C, Gray E, Hartley J . The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol. 2014; 15(9):839-45. PMC: 4139417. DOI: 10.1038/ni.2948. View

16.

Musto P, Simeon V, Martorelli M, Petrucci M, Cascavilla N, Di Raimondo F . Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2013; 28(1):222-5. DOI: 10.1038/leu.2013.241. View

17.

Walker B, Wardell C, Melchor L, Hulkki S, Potter N, Johnson D . Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120(5):1077-86. DOI: 10.1182/blood-2012-03-412981. View

18.

Albarracin F, Fonseca R . Plasma cell leukemia. Blood Rev. 2011; 25(3):107-12. PMC: 3907188. DOI: 10.1016/j.blre.2011.01.005. View

19.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F . Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer. 2004; 42(2):117-27. DOI: 10.1002/gcc.20123. View

20.

Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I . A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009; 48(7):603-14. DOI: 10.1002/gcc.20668. View